Orally active histone deacetylase (HDAC) inhibitor, IC\textsubscript{50} = 0.9, 0.9, 1.2 and >20 μM for HDAC1, HDAC2, HDAC3 and HDAC8 respectively\textsuperscript{1}. Mediates G\textsubscript{1} cell cycle arrest, inhibits proliferation and induces apoptosis \textit{in vitro} and \textit{in vivo}\textsuperscript{2,3}. Increases neuroplasticity during memory extinction\textsuperscript{4}. Protects beta cells from cytokine-induced apoptosis\textsuperscript{4}.

2) Beckers \textit{et al}. (2007), \textit{Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group}; Int. J. Cancer, 121 1138

**PHYSICAL DATA**

- Molecular Weight: 269.30
- Molecular Formula: C\textsubscript{15}H\textsubscript{15}N\textsubscript{3}O\textsubscript{2}
- Purity: 98% by HPLC
- NMR: (Conforms)
- Solubility: DMSO (up to 25 mg/ml)
- Physical Description: Off-white solid
- Storage and Stability: Store as supplied desiccated at -20°C for up to 1 year from the date of purchase. Solutions in DMSO may be stored at -20°C for up to 1 month.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.